Advancements in the Development of Anti-SARS-CoV-2 Therapeutics

Int J Mol Sci. 2024 Oct 9;25(19):10820. doi: 10.3390/ijms251910820.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, and so far, it has occurred five noteworthy variants of concern (VOC). SARS-CoV-2 invades cells by contacting its Spike (S) protein to its receptor on the host cell, angiotensin-converting enzyme 2 (ACE2). However, the high frequency of mutations in the S protein has limited the effectiveness of existing drugs against SARS-CoV-2 variants, particularly the Omicron variant. Therefore, it is critical to develop drugs that have highly effective antiviral activity against both SARS-CoV-2 and its variants in the future. This review provides an overview of the mechanism of SARS-CoV-2 infection and the current progress on anti-SARS-CoV-2 drugs.

Keywords: COVID-19; Omicron; SARS-CoV-2; drug development.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2* / genetics
  • Angiotensin-Converting Enzyme 2* / metabolism
  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Humans
  • SARS-CoV-2* / drug effects
  • Spike Glycoprotein, Coronavirus* / genetics
  • Spike Glycoprotein, Coronavirus* / metabolism

Substances

  • Antiviral Agents
  • Spike Glycoprotein, Coronavirus
  • Angiotensin-Converting Enzyme 2
  • spike protein, SARS-CoV-2
  • ACE2 protein, human

Supplementary concepts

  • SARS-CoV-2 variants